SOL-804: Prostate cancer treatment

• Bukwang’s formulation-focused subsidiary, Dyna Therapeutics (KR) has entered exclusive option agreement with Solural Pharm to license patented SOL-804 for WW right
   

• SOL-804: new formulation of currently available drug with Lymphatic Targeting Technology
  - Eliminates food effect
  - Better safety profile due to reduced dosing level
   

• Preclinical in 2017